vital status determination

OTHER2 trials

Sponsors

Assistance Publique Hopitaux De Marseille, Centre Hospitalier Universitaire de Nice

Conditions

Acute Myeloid LeukemiaVenous Thromboembolism (VTE)

Unknown Phase

Identification of New Genetic Markers for the Risk of Recurrence of Venous Thromboembolism by Whole Genome Analysis

CompletedNCT03977870

Assistance Publique Hopitaux De MarseilleVenous Thromboembolism (VTE)

Start: 2018-07-01End: 2023-08-03Updated: 2023-08-04

Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

CompletedNCT06030089

Centre Hospitalier Universitaire de NiceAcute Myeloid Leukemia

Start: 2024-02-26End: 2025-03-03Updated: 2025-12-16

Related Papers

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

Blood2025-11-03